513 related articles for article (PubMed ID: 32024543)
21. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
22. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
[TBL] [Abstract][Full Text] [Related]
23. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
24. Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.
Yan F; Pang J; Peng Y; Molina JR; Yang P; Liu S
PLoS One; 2016; 11(9):e0162925. PubMed ID: 27610620
[TBL] [Abstract][Full Text] [Related]
25. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
[No Abstract] [Full Text] [Related]
26. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
[TBL] [Abstract][Full Text] [Related]
27. Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.
Jiang Z; Yang Y; Yang Y; Zhang Y; Yue Z; Pan Z; Ren X
Biomed Pharmacother; 2017 Dec; 96():378-383. PubMed ID: 29031195
[TBL] [Abstract][Full Text] [Related]
28. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
[TBL] [Abstract][Full Text] [Related]
29. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
[TBL] [Abstract][Full Text] [Related]
30. Stimulation of Fas/FasL-mediated apoptosis by luteolin through enhancement of histone H3 acetylation and c-Jun activation in HL-60 leukemia cells.
Wang SW; Chen YR; Chow JM; Chien MH; Yang SF; Wen YC; Lee WJ; Tseng TH
Mol Carcinog; 2018 Jul; 57(7):866-877. PubMed ID: 29566277
[TBL] [Abstract][Full Text] [Related]
31. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
32. DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Li J; Yu T; Yan M; Zhang X; Liao L; Zhu M; Lin H; Pan H; Yao M
Exp Cell Res; 2019 Jan; 374(2):304-314. PubMed ID: 30528265
[TBL] [Abstract][Full Text] [Related]
33. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
35. Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.
Zhao K; Zhang Q; Flanagan SA; Lang X; Jiang L; Parsels LA; Parsels JD; Zou W; Lawrence TS; Buisson R; Green MD; Morgan MA
Mol Cancer Res; 2021 Sep; 19(9):1571-1582. PubMed ID: 34045311
[TBL] [Abstract][Full Text] [Related]
36. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
[TBL] [Abstract][Full Text] [Related]
37. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma.
Ma H; Chang H; Yang W; Lu Y; Hu J; Jin S
Mol Cancer; 2020 Jan; 19(1):4. PubMed ID: 31907020
[TBL] [Abstract][Full Text] [Related]
38. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
39. Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells.
Xia Y; Yang W; Bu W; Ji H; Zhao X; Zheng Y; Lin X; Li Y; Lu Z
J Biol Chem; 2013 Jul; 288(27):19321-9. PubMed ID: 23678002
[TBL] [Abstract][Full Text] [Related]
40. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
